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Abstract: The pill burden of patients with hypertension and dyslipidemia can result in poor medi-
cation compliance. This study aimed to evaluate the efficacy and safety of fixed-dose combination 
(FDC) therapy with olmesartan medoxomil (40 mg) and rosuvastatin (20 mg) in Korean patients 
with mild to moderate hypertension and dyslipidemia. This multicenter, randomized, double-blind, 
factorial-design study included patients aged $20 years with mild to moderate essential hyperten-
sion and dyslipidemia. Patients were randomly assigned to receive FDC therapy (40 mg olmesartan 
medoxomil, 20 mg rosuvastatin), 40 mg olmesartan medoxomil, 20 mg rosuvastatin, or a placebo. 
The percentage change from baseline in low-density lipoprotein cholesterol levels was compared 
between FDC therapy and olmesartan medoxomil, and the change from baseline in diastolic blood 
pressure was compared between FDC therapy and rosuvastatin 8 weeks after treatment. A total of 
162 patients were included. The least square mean percentage change (standard error) from baseline 
in low-density lipoprotein cholesterol levels 8 weeks after treatment was significantly greater in the 
FDC than in the olmesartan medoxomil group (−52.3% [2.8%] vs −0.6% [3.5%], P,0.0001), and 
the difference was −51.7% (4.1%) (95% confidence interval: −59.8% to −43.6%). The least square 
mean change (standard error) from baseline in diastolic blood pressure 8 weeks after treatment 
was significantly greater in the FDC group than in the rosuvastatin group (−10.4 [1.2] mmHg vs 
0.1 [1.6] mmHg, P,0.0001), and the difference was −10.5 (1.8) mmHg (95% confidence inter-
val: −14.1 to −6.9 mmHg). There were 50 adverse events in 41 patients (22.7%) and eight adverse 
drug reactions in five patients (2.8%). The study found that FDC therapy with olmesartan medoxomil 
and rosuvastatin is an effective, safe treatment for patients with hypertension and dyslipidemia. This 
combination may improve medication compliance in patients with a large pill burden.
Keywords: fixed-dose combination therapy, olmesartan medoxomil, rosuvastatin, hypertension, 
dyslipidemia
Introduction
The coexistence of hypertension and dyslipidemia, which are central to the pathogenesis 
of coronary heart disease, has been reported to be prevalent.1–4 The risk of coronary 
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heart disease with the coexistence of hypertension and dys-
lipidemia has been reported to be higher than the sum of the 
risks of coronary heart disease with each of the component 
factors.4–6 As cardiovascular risk factors interact with each 
other, comprehensive control of both blood pressure (BP) 
and blood cholesterol level is effective for reducing the risk 
of future cardiovascular events.6,7
In clinical practice, the pill burden in patients with both 
hypertension and dyslipidemia can result in poor adherence 
and persistence with the prescribed drugs.8 A fixed-dose 
combination (FDC) of a BP-lowering agent and statin could 
improve adherence and persistence in patients with multiple 
risk factors, resulting in a reduction of the risks of future 
cardiovascular events.
In our previous study, the coadministration of ol mesartan 
medoxomil (40 mg) and rosuvastatin (20 mg) did not sig-
nificantly influence each other’s pharmacokinetics without 
adverse events (AEs).9 In healthy volunteers, FDC therapy 
with olmesartan medoxomil (40 mg) and rosuvastatin 
(20 mg) had a similar pharmacokinetic profile to that of 
coadministration of each drug as individual tablets.10 The 
present study aimed to evaluate the efficacy and safety of 
FDC therapy with olmesartan medoxomil (40 mg) and rosu-
vastatin (20 mg) in Korean patients with mild to moderate 
hypertension and dyslipidemia.
Materials and methods
study design
This was a randomized, double-blind, factorial-design study 
performed at 25 locations in Korea between September 2012 
and May 2013 (Table S1). This study was designed to adhere 
to the Korean Good Clinical Practice guidelines, related 
regulations in Korea, and the Declaration of Helsinki, and 
it was approved by the Ministry of Food and Drug Safety, 
and the institutional review boards of each of the participat-
ing institutions (Table S1) (ClinicalTrials.gov Identifier: 
NCT01764295).
Screening was performed after patients signed a written 
informed consent form for participation in this study. After 
assessing the screening results of the patients, those who 
satisfied the inclusion criteria underwent therapeutic lifestyle 
change for a period of .4 weeks. After the therapeutic lifestyle 
change period, central laboratory tests and BP measurements 
for final decisions were performed at the baseline visit. After 
a qualification period of ,1 week, the selected patients were 
randomly allocated to the following four groups: the FDC 
therapy group (olmesartan medoxomil [40 mg] and rosuvas-
tatin [20 mg], DWJ1276, Daewoong Pharmaceuticals, Seoul, 
Korea); olmesartan medoxomil group (olmesartan medoxomil 
[40 mg], Olmetec®, Daiichi Sankyo, Tokyo, Japan); rosuvas-
tatin group (rosuvastatin [20 mg], Crestor®, AstraZeneca plc, 
London, UK); and placebo group. Each placebo tablet had an 
appearance and an odor identical to that of the active tablets. The 
pills were completely indistinguishable. All randomly assigned 
subjects took three tablets of investigational drugs orally once 
a day for 8 weeks at the same time each day. For randomiza-
tion, this study used a stratified block randomization method 
stratified according to the low-density lipoprotein cholesterol 
(LDL-C) (100 mg/dL # LDL-C ,130 mg/dL, 130 mg/dL 
# LDL-C ,160 mg/dL, LDL-C $160 mg/dL) level and dia-
stolic blood pressure (DBP) (90 mmHg # DBP ,100 mmHg, 
DBP $100 mmHg, in case of subjects with diabetes or 
chronic renal disease, 80 mmHg # DBP ,90 mmHg, 
DBP $90 mmHg). The randomization code was generated 
with the proc plan procedure using SAS version 9.2 (SAS 
Institute Inc., Cary, NC, USA) by an independent statistician of 
the contract research organization. The independent statistician 
made an extra “randomization list with investigational drug 
number”. The investigators and the pharmacists used this list 
for prescription of investigational drugs. All the investigators, 
participants, and study staffs remained blinded to treatment 
group until study completion.
Patients stopped taking any antihypertensive drugs at 
least 2 weeks before randomization and stopped taking lipid-
lowering drugs during the entire therapeutic lifestyle change 
period. In addition, antihypertensive and lipid-lowering drugs 
that could interact with the study drugs were discontinued 
during the treatment period. During the study period, the 
patients visited the participating institutions five times as 
follows: screening visit, baseline visit, randomization visit, 
and visits at weeks 4 and 8 after starting treatment. The fol-
lowing procedures were carried out at each visit: physical 
examination, vital signs (DBP/systolic blood pressure [SBP], 
temperature, and pulse), laboratory tests (hematology, chem-
istry, and urinalysis), assessment of compliance, and AEs.
When the subject showed signs or symptoms of hypoten-
sion with SBP ,90 mmHg or DBP ,60 mmHg, hypertension 
with SBP $180 mmHg or DBP $110 mmHg, and abnormal 
results values of liver function (aspartate aminotransferase 
and alanine aminotransferase three times greater than upper 
limit of normal level), the subject had to discontinue this 
study for his or her safety.
inclusion and exclusion criteria
The study recruited patients aged $20 years with mild to mod-
erate essential hypertension and dyslipidemia, as defined by the 
Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure 
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(JNC VII) and the National Cholesterol Education Program 
Adult Treatment Panel III (NCEP ATP III) (Table 1).
Patients were excluded if they had secondary hyperten-
sion (medical history of secondary hypertension or suspected 
secondary hypertension by physician) or dyslipidemia; 
hypersensitivity to olmesartan medoxomil or rosuvastatin; 
uncontrolled diabetes mellitus (hemoglobin A1c $9% or fast-
ing plasma glucose level $160 mg/dL); myocardial infarc-
tion, transient ischemic attack, percutaneous transluminal 
coronary angioplasty, or unstable angina within the previous 
6 months; severe heart failure (New York Heart Association 
class 3 and 4); thyroid stimulating hormone levels $1.5 times 
the upper normal limit; creatinine level $1.5 times the upper 
normal limit; creatinine kinase, aspartate aminotransferase, 
and alanine aminotransferase levels $2 times the upper 
normal limits; triglyceride levels $400 mg/dL; or any disease 
that could influence the study results.
Objectives and outcome measures
The primary objectives were to determine the superiority of 
FDC therapy over olmesartan medoxomil (40 mg) for the 
percentage change from baseline in the LDL-C level and the 
superiority of FDC therapy over rosuvastatin (20 mg) for 
the change from baseline in DBP at week 8.
The secondary objectives were to compare the FDC 
therapy to olmesartan medoxomil (40 mg) for the change 
from baseline in DBP and the FDC therapy to rosuvastatin 
(20 mg) for the percentage change from baseline in the 
LDL-C level at week 8. The additional secondary objectives 
were to compare the FDC therapy to olmesartan medoxomil 
(40 mg) and rosuvastatin (20 mg) for the percentage change 
from baseline in the total cholesterol, triglyceride, and high-
density lipoprotein cholesterol levels at weeks 4 and 8; the 
change from baseline in SBP at weeks 4 and 8; and the 
percentage of patients who achieved the treatment goals 
(LDL-C ,160 mg/dL, 130 mg/dL, 100 mg/dL each category 
according to the risk factors and a 10-year risk assessment, 
SBP/DBP ,140/90 mmHg, in case of subjects with diabetes 
or chronic renal disease, 130/80 mmHg) defined by the NCEP 
ATP III and JNC VII at week 8.
For reliability evaluations, the percentage change from 
baseline in the LDL-C level and the change from baseline 
in DBP were compared between FDC therapy and placebo 
at week 8.
For safety evaluations, the dates of onset of AEs and 
termination, severity of AEs, actions taken for the AEs, 
and relationships of the AEs with the study products were 
assessed at each visit. In addition, abnormal vital signs, 
laboratory test results (including hematology, biochemistry, 
and urinalysis), physical examination results, and echocar-
diography results were recorded.
statistical analysis
The hypotheses being tested were that the FDC therapy was 
superior to olmesartan medoxomil (40 mg) in reducing the 
LDL-C level and superior to rosuvastatin (20 mg) in reduc-
ing DBP. The expected difference of the mean percentage 
change from baseline in the LDL-C level between FDC 
therapy and olmesartan medoxomil (40 mg) was −53.8% 
(standard deviation: 20%) and the expected difference of the 
mean change from baseline in DBP between FDC therapy 
and rosuvastatin (20 mg) was −6 mmHg (standard deviation: 
8.7 mmHg). Finally, the sample sizes were calculated using 
the percent change of LDL-C level and the change in DBP. 
The sample size identified for assessing the change in DBP, 
which was larger, was selected. For collecting more safety 
data of FDC therapy, the randomization ratio was set into 
2:1:1:1. According to the randomization ratio of 2:1:1:1 and 
a 20% drop-out rate, a sample size of 150 patients was calcu-
lated (60 patients in the FDC therapy group and 30 patients 
each in the olmesartan medoxomil, rosuvastatin, and placebo 
groups). As both the hypotheses required significant findings 
Table 1 Inclusion criteria according to risk factors and a 10-year risk assessment
Category LDL-C level (mg/dL) DBP (mmHg)
1. Person without risk factorsa other than hypertension and dyslipidemia 160–250 90–109 (patients with 
DM, cKD: 80–99)2. Person with more than one risk factora other than hypertension and dyslipidemia and 
with a ,10% risk in the 10-year risk assessment
160–250
3. Person with more than one risk factora other than hypertension and dyslipidemia and 
with a 10%–20% risk in the 10-year risk assessment
130–250
4. Person with coronary heart disease or equivalentb or with a .20% risk in the  
10-year risk assessment
100–250
Notes: aRisk factors: a) Cigarette smoking; b) HDL-C level ,40 mg/dL; c) family history of premature coronary heart disease (male first degree relative ,55 years; female 
first degree relative ,65 years); and d) age (males $45 years; females $55 years). HDL-C level $60 mg/dL counts as a “negative” risk factor; its presence excludes one risk 
factor from the total count. bPatients with carotid artery disease, peripheral vascular disease, abdominal aortic aneurysm, and type 2 DM.
Abbreviations: CKD, chronic kidney disease; DBP, diastolic blood pressure; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol.
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for acceptance, each individual significance level was set at 
5% for the entire hypothesis and the statistical power for 
each hypothesis was set at 80%.
Continuous data were summarized using descriptive 
statistics, and the treatment groups were compared using 
analysis of covariance, with baseline values, stratification 
factors (risk factors and BP), and drug interaction variables 
as covariates. Categorical data were analyzed using logistic 
regression models, with stratification factors and drug inter-
action variables as covariates. All analyses were two-sided, 
and the significance level was α=0.05. The analyses were 
performed using SAS version 9.2 (SAS Institute Inc.).
Results
Patients’ characteristics
A total of 423 patients underwent the screening examina-
tion, and of these patients, 183 who were found to be suit-
able for this study were randomized. Of these 183 patients, 
181 patients were administered the investigational products. 
However, 19 patients were excluded based on the inclusion/
exclusion criteria. Therefore, 162 patients completed 
the treatment and were included in the full analysis set 
(Figure 1).
The demographics of the full analysis set according to 
the treatment group are presented in Table 2. The mean 
(standard deviation) age of the patients was 61.4 (7.8) 
years, and the mean body mass index was 25.4 (2.7) kg/m2. 
The mean SBP was 150.5 (13.5) mmHg, and the mean 
DBP was 92.6 (6.6) mmHg. The mean LDL-C level was 
154.5 (31.7) mg/dL, and the mean high-density lipopro-
tein cholesterol, triglyceride, and total cholesterol levels 
were 50.0 (11.4) mg/dL, 147.7 (67.2) mg/dL, and 230.2 
(36.3) mg/dL, respectively. There were no significant dif-
ferences in demographic characteristics, except for family 
history of premature coronary heart disease, among the treat-
ment groups (P=0.0118).
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Figure 1 Study flowchart.
Abbreviations: BP, blood pressure; FAS, full analysis set; FDC, fixed dose combination; IP, investigational product; SAEs, serious adverse events.
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lipid parameters
The least square mean percentage changes (standard error) 
from baseline in the LDL-C level 8 weeks after treatment 
were −52.3% (2.8%) in the FDC therapy group, −0.6% 
(3.5%) in the olmesartan medoxomil group, and −46.9% 
(3.5%) in the rosuvastatin group. The difference between 
the FDC and olmesartan medoxomil groups was −51.7% 
(4.1%) (95% confidence interval [CI]: −59.8% to −43.6%), 
and the percentage change was significantly higher in the 
FDC therapy group than in the olmesartan medoxomil group 
(P,0.0001). The difference between the FDC therapy and 
rosuvastatin groups was −5.4% (4.1%) (95% CI: −13.5% to 
2.7%), and the percentage change was not significantly dif-
ferent between the FDC and rosuvastatin groups (P=0.1864). 
The percentage changes in LDL-C levels at weeks 4 and 8 
are presented in Table 3, and the percentage changes in other 
lipid parameters at weeks 4 and 8 are presented in Table 4.
The treatment goal was achieved at 8 weeks in 90.2% 
(55/61) of patients from the FDC therapy group, 16.7% (6/36) 
of patients from the olmesartan medoxomil group, 86.1% 
(31/36) of patients from the rosuvastatin group, and 17.2% 
(5/29) of patients from the placebo group. The percentage 
of patients who achieved the treatment goal was sig-
nificantly higher in the FDC therapy group than in the 
 olmesartan medoxomil and placebo groups (both P,0.0001). 
There was no significant difference in the percentage 
of patients between the FDC therapy and rosuvastatin 
groups (P=0.5111, Figure 2A).
Blood pressure
The least square mean changes (standard error) from 
baseline in DBP at 8 weeks after treatment were 
−10.4 (1.2) mmHg in the FDC therapy group, 0.1 (1.6) 
mmHg in the rosuvastatin group, and −8.1 (1.5) mmHg in 
the olmesartan medoxomil group. The difference between 
the FDC therapy and rosuvastatin groups was −10.5 (1.8) 
mmHg (95% CI: −14.1 to −6.9 mmHg), and the change was 
significantly higher in the FDC therapy group than in the 
Table 2 Demographics and baseline characteristics prior to randomization in the full analysis set
Characteristic* FDC therapy 
group (n=61)
Olmesartan medoxomil 
group (n=36)
Rosuvastatin 
group (n=36)
Placebo 
group (n=29)
Total (n=162)
Age (years) 61.9 (8.1) 59.5 (6.9) 61.8 (8.0) 62.5 (8.2) 61.4 (7.8)
Height (cm) 162.8 (8.6) 163.7 (7.0) 163.9 (8.4) 165.2 (8.6) 163.7 (8.2)
Weight (kg) 67.5 (9.3) 69.0 (9.3) 69.1 (11.7) 67.4 (9.9) 68.2 (10.0)
BMI (kg/m2) 25.4 (2.4) 25.7 (2.6) 25.6 (3.0) 24.7 (2.8) 25.4 (2.7)
Sex, n (%)
Male 34 (55.7) 24 (66.7) 25 (69.4) 21 (72.4) 104 (64.2)
Female 27 (44.3) 12 (33.3) 11 (30.6) 8 (27.6) 58 (35.8)
Lipid parameters (mg/dL)
LDL-C 154.4 (32.2) 156.7 (34.5) 154.0 (28.2) 152.5 (32.7) 154.5 (31.7)
HDL-C 48.9 (10.8) 52.1 (12.3) 50.7 (12.0) 48.6 (11.1) 50.0 (11.4)
Triglyceride 152.3 (72.4) 145.6 (58.1) 132.3 (54.9) 160.0 (79.1) 147.7 (67.2)
Total cholesterol 230.5 (37.6) 233.3 (38.3) 227.4 (32.3) 228.9 (37.0) 230.2 (36.3)
Blood pressure (mmHg)
systolic 150.6 (11.9) 150.6 (15.5) 148.9 (13.3) 152.2 (14.5) 150.5 (13.5)
Diastolic 92.0 (7.4) 93.3 (5.0) 92.9 (6.5) 92.5 (7.0) 92.6 (6.6)
Concurrent history, n (%)
Diabetes mellitus
Yes 27 (44.3) 14 (38.9) 8 (22.2) 9 (31.0) 58 (35.8)
no 34 (55.7) 22 (61.1) 28 (77.8) 20 (69.0) 104 (64.2)
Chronic kidney disease
Yes 1 (1.6) 1 (2.8) 3 (8.3) 2 (6.9) 7 (4.3)
no 60 (98.4) 35 (97.2) 33 (91.7) 27 (93.1) 155 (95.7)
Smoking status, n (%)
Nonsmoker 40 (65.6) 22 (61.1) 20 (55.6) 13 (44.8) 95 (58.6)
Current smoker 8 (13.1) 5 (13.9) 7 (19.4) 6 (20.7) 26 (16.1)
Ex-smoker 13 (21.3) 9 (25.0) 9 (25.0) 10 (34.5) 41 (25.3)
Family history of early CHD, n (%)
Yes 2 (3.3) 3 (8.3) 7 (19.4) 0 (0.0) 12 (7.4)
no 59 (96.7) 33 (91.7) 29 (80.6) 29 (100.0) 150 (92.6)
Notes: Data are presented as mean (standard deviation) unless otherwise specified. *There were no significant differences among the treatment groups except for family 
history of early chD.
Abbreviations: BMI, body mass index; CHD, coronary heart disease; FDC, fixed-dose combination; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol.
Drug Design, Development and Therapy 2016:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2604
Park et al
Table 3 Changes in the low-density lipoprotein cholesterol level at weeks 4 and 8 in the full analysis set
FDC therapy 
group (n=61)
Olmesartan medoxomil 
group (n=36)
Rosuvastatin 
group (n=36)
Placebo  
group (n=29)
Week 4
Mean (SD), mg/dL 74.6 (32.0) 153.3 (40.3) 80.2 (27.2) 140.0 (45.9)
LS mean percent change from baseline (SE), % −51.2 (2.8) −1.2 (3.4) −47.8 (3.5) −7.8 (3.8)
LS mean difference, % (SE) (95% CI) – −50.0 (4.1) (−58.0 to 42.0) −3.4 (4.1) (−11.4 to 4.6) −43.4 (4.4) (−52.0 to 43.8)
P-value* vs FDC therapy – ,0.0001 0.4034 ,0.0001
Week 8
Mean (SD), mg/dL 72.4 (27.2) 153.5 (40.6) 80.7 (34.5) 146.7 (48.6)
LS mean percentage change from baseline (SE), % −52.3 (2.8) −0.6 (3.5) −46.9 (3.5) −3.2 (3.9)
LS mean difference, % (SE) (95% CI) – −51.7 (4.1) (−59.8 to −43.6) −5.4 (4.1) (−13.5 to 2.7) −49.1 (4.4) (−57.8 to −40.4)
P-value* vs FDC therapy – ,0.0001 0.1864 ,0.0001
Note: *analysis of covariance.
Abbreviations: CI, confidence interval; FDC, fixed-dose combination; LS, least square; SD, standard deviation; SE, standard error.
Table 4 Least square mean percentage change from baseline in the total cholesterol, triglyceride and high-density lipoprotein 
cholesterol levels at weeks 4 and 8 in the full analysis set
Parameter FDC therapy 
group (n=61)
Olmesartan medoxomil 
group (n=36)
Rosuvastatin  
group (n=36)
Placebo  
group (n=29)
Week 4
Total cholesterol, ls mean percent 
change from baseline (SE), %
−36.1 (1.9) −1.1 (2.4) −33.9 (2.4) −3.5 (2.6)
LS mean difference, % (SE) (95% CI) – −35.0* (2.8) (−40.6 to 29.4) −2.23*** (2.8) (−7.8 to 3.3) −32.6* (3.3) (−38.6 to 26.6)
Triglyceride ls mean percent 
change from baseline (SE), %
−15.5 (5.6) 9.5 (7.0) −8.7 (7.2) 15.7 (7.9)
LS mean difference, % (SE) (95% CI) – −25.0** (8.6) (−42.0 to 8.1) −6.8*** (8.6) (−23.9 to 10.3) −31.2** (9.2) (−49.5 to 13.0)
HDL-C, LS mean percent change 
from baseline (SE), %
8.0 (2.1) 1.1 (2.7) 5.8 (2.7) 6.2 (3.0)
LS mean difference, % (SE) (95% CI) – 6.9** (3.3) (0.5 to 13.3) 2.2*** (3.3) (−4.2 to 8.6) 1.8*** (3.5) (−5.1 to 8.6)
Week 8
Total cholesterol, ls mean percent 
change from baseline (SE), %
−37.1 (2.0) −0.7 (2.5) −32.8 (2.6) −2.4 (2.8)
LS mean difference, % (SE) (95% CI) −36.4* (3.0) (−42.3 to 30.1) −4.35*** (3.0) (−10.3 to 1.6) −34.7* (3.2) (−41.1 to 28.4)
Triglyceride, ls mean percent 
change from baseline (SE), %
−13.7 (6.4) 17.8 (8.0) −8.1 (8.2) 0.9 (9.0)
LS mean difference, % (SE) (95% CI) −31.4** (9.7) (−50.6 to 12.2) −5.6*** (9.8) (−24.9 to 13.7) −14.6*** (10.4) (−35.2 to 6.1)
HDL-C, LS mean percent change 
from baseline (SE), %
6.9 (2.2) −1.2 (2.8) 5.3 (2.8) 9.7 (3.1)
LS mean difference, % (SE) (95% CI) 8.1** (3.4) (1.4 to 14.8) 1.5*** (3.4) (−5.6 to 8.2) −2.8*** (3.6) (−10.0 to 4.4)
Notes: *P,0.0001; **P,0.05; ***P.0.05 (analysis of covariance) vs FDC therapy.
Abbreviations: CI, confidence interval; FDC, fixed-dose combination; HDL-C, high-density lipoprotein cholesterol; LS, least square; SE, standard error.
rosuvastatin group (P,0.0001). The difference between 
the FDC therapy and olmesartan medoxomil groups 
was −2.3 (1.8) mmHg (95% CI: −5.9 to 1.3 mmHg), and 
the change was not significantly different between the FDC 
therapy and olmesartan medoxomil groups (P=0.2096). 
The changes in DBP at 4 weeks and the changes in SBP 
at 4 and 8 weeks were similar to the changes in DBP at 8 
weeks (Table 5).
The treatment goal was achieved at 8 weeks in 57.4% 
(35/61) of patients from the FDC therapy group, 11.1% 
(4/36) of patients from the rosuvastatin group, 41.7% 
(15/36) of patients from the olmesartan medoxomil group, 
and 20.7% (6/29) of patients from the placebo group. 
The percentage of patients who achieved the treatment 
goal was significantly higher in the FDC therapy group 
than in the rosuvastatin and placebo groups (P,0.0001, 
P=0.0018, respectively). There was no significant 
difference in the percentage of patients between the 
FDC and olmesartan medoxomil groups (P=0.1360, 
Figure 2B).
safety
Safety analysis was performed in all the patients who were 
administered the investigational products one or more times. 
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Figure 2 Percentage of patients who achieved the treatment goals of low-density lipoprotein cholesterol levels and blood pressure at week 8 in the full analysis set.
Notes: (A) Percentage of patient who achieved the treatment goal of low-density lipoprotein cholesterol levels defined by the National Cholesterol Education Program 
Adult Treatment Panel III. Goal was defined as low-density lipoprotein cholesterol level ,100, 130, or 160 mg/dL depending on the risk profile. (B) Percentage of patients 
who achieved the treatment goal of blood pressure defined by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure. Goal was defined as DBP ,90 mmHg (or ,80 mmHg in patients with diabetes mellitus or chronic kidney disease).
Abbreviations: DBP, diastolic blood pressure; FDC, fixed-dose combination.
Table 5 Changes in blood pressure at weeks 4 and 8 in the full analysis set
FDC therapy 
group (n=61)
Olmesartan medoxomil 
group (n=36)
Rosuvastatin  
group (n=36)
Placebo  
group (n=29)
Diastolic blood pressure
Week 4
Mean (SD), mmHg 84.8 (8.5) 86.0 (7.9) 90.9 (7.0) 92.7 (8.6)
LS mean change from baseline (SE), 
mmhg
−7.4 (1.1) −6.7 (1.4) −1.6 (1.4) 0.4 (1.5)
LS mean difference, mmHg (SE) (95% CI) – −0.7 (1.6) (−3.9 to 2.5) −5.7 (1.6) (−9.0 to −2.5) −7.7 (1.8) (−11.2 to 4.3)
P-value* vs FDC therapy – 0.6695 0.0006 ,0.0001
Week 8
Mean (SD), mmHg 82.1 (9.8) 85.0 (8.3) 93.0 (9.2) 92.9 (8.7)
LS mean change from baseline (SE), 
mmhg
−10.4 (1.2) −8.1 (1.5) 0.1 (1.6) 0.2 (1.7)
LS mean difference, mmHg (SE) (95% CI) – −2.3 (1.8) (−5.9 to 1.3) −10.5 (1.8) (−14.1 to −6.9) −10.5 (2.0) (−14.4 to −6.7)
P-value* vs FDC therapy – 0.2096 ,0.0001 ,0.0001
Systolic blood pressure
Week 4
Mean (SD), mmHg 135.6 (14.8) 133.9 (13.5) 150.2 (17.1) 151.5 (18.3)
LS mean change from baseline  
(SE), mmHg
−14.8 (2.1) −16.5 (2.6) 0.4 (2.6) 0.2 (2.9)
LS mean difference, mmHg (SE) (95% CI) – 1.6 (3.1) (−4.5 to 7.8) −15.3 (3.1) (−21.4 to −9.1) −15.1 (3.3) (−21.7 to −8.5)
P-value* vs FDC therapy – 0.5996 ,0.0001 ,0.0001
Week 8
Mean (SD), mmHg 132.6 (17.9) 133.4 (14.5) 153.4 (19.1) 154.2 (21.0)
LS mean change from baseline  
(SE), mmHg
−18.7 (2.3) −17.9 (2.9) 2.9 (2.9) 1.75 (3.3)
LS mean difference, mmHg (SE) (95% CI) – −0.8 (3.5) (−7.8 to 6.1) −21.6 (3.5) (−28.5 to −14.7) −20.4 (3.8) (−27.9 to −13.0)
P-value* vs FDC therapy – 0.8147 ,0.0001 ,0.0001
Note: *analysis of covariance.
Abbreviations: CI, confidence interval; FDC, fixed-dose combination; LS, least square; SD, standard deviation; SE, standard error.
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A total of 181 patients (71 patients in the FDC therapy group, 
38 patients in the olmesartan medoxomil group, 38 patients in 
the rosuvastatin group, and 34 patients in the placebo group) 
were included in the safety set. The summary of AEs reported 
during the study period is presented in Table 6. Among the 
181 patients, 41 (22.7%, 50 cases) experienced AEs during 
the study period. Every AE was reported regardless of the 
causal relationship.
There were no significant differences in the incidences 
of AEs and adverse drug reactions (ADRs) among the treat-
ment groups (P=0.9202, and P=0.5990, respectively). Most 
of the AEs were mild, and severe AEs were not reported in 
any of the treatment groups.
Serious AEs occurred in two patients (1.1%, two cases): 
one patient had myocardial infarction and was from the olm-
esartan medoxomil group, while the other patient who had 
subarachinoid hemorrhage was from the rosuvastatin group. 
The investigational products were immediately discontinued 
in these patients. However, all serious AEs were not likely 
related to investigational drugs and they were resolved 
without sequelae.
A total of five patients experienced eight ADRs during 
the study period. In the FDC therapy group, two patients 
reported ADRs. Of these two patients, one had increases 
in aspartate aminotransferase and alanine aminotransferase 
levels and the other had an increase in blood creatinine levels 
and a decrease in creatinine clearance. All the ADRs were 
expected side effects of the approved drugs.
Discussion
The present study demonstrated that FDC therapy with olm-
esartan medoxomil (40 mg) and rosuvastatin (20 mg) was 
highly effective for achieving the therapeutic goals of the 
LDL-C level and BP. In the reduction of the LDL-C level, 
the effectiveness of FDC therapy was not different from 
that of rosuvastatin (20 mg), and in the reduction of BP, the 
effectiveness of FDC therapy was not different from that of 
olmesartan medoxomil (40 mg). Additionally, we found that 
FDC therapy was generally safe and well tolerated.
Olmesartan medoxomil is a selective angiotensin II type 1 
receptor blocker (ARB) with proven BP-lowering efficacy.11,12 
The antihypertensive efficacy of ARBs has been shown to 
be at least equivalent to the efficacies of other major classes 
of antihypertensive agents but with a better tolerability 
profile.13 Several studies have demonstrated that ARBs have 
positive effects on left ventricular hypertrophy, endothelial 
dysfunction, and atherosclerosis, suggesting that ARBs offer 
cardiovascular protective benefits in addition to their favor-
able effects on BP.14,15 Olmesartan medoxomil has a more 
rapid onset of action than that of other ARBs, with signifi-
cant improvements in efficacy.11 The ability of olmesartan 
medoxomil to effectively reduce BP suggests that it is a good 
therapeutic option for intensive treatment in patients with 
mild to moderate hypertension.12
Statins are usually used to treat dyslipidemia and manage 
patients with ischemic heart disease. However, with the comple-
tion of many large clinical trials on statins over the past 10 years, 
Table 6 summary of aes and adverse drug reactions in the safety set
FDC therapy 
group (n=71)
Olmesartan medoxomil 
group (n=38)
Rosuvastatin 
group (n=38)
Placebo 
group (n=34)
Total (N=181)
Number of patients with AEs* 17 (23.9) [23] 7 (18.4) [7] 9 (23.7) [11] 8 (23.5) [9] 41 (22.7) [50]
P-value 0.9202**
Severity, number of AEs
Mild 18 4 8 7 37
Moderate 5 3 3 2 13
severe 0 0 0 0 0
Number of patients with SAEs (%) 0 1 (2.6) 1 (2.6) 0 2 (1.1)
P-value 0.3680**
adverse drug reactions* 2 (2.8) [4] 0 2 (5.3) [3] 1 (2.9) [1] 5 (2.8) [8]
P-value 0.5990**
alT increased 1 (1.4) [1] 0 0 1 (0.6) [1]
asT increased 1 (1.4) [1] 0 0 1 (0.6) [1]
Blood creatinine increased 1 (1.4) [1] 0 0 1 (0.6) [1]
ccr decreased 1 (1.4) [1] 0 0 1 (0.6) [1]
Blood triglycerides increased 0 0 1 (2.9) [1] 1 (0.6) [1]
headache 0 2 (5.3) [2] 0 2 (1.1) [2]
insomnia 0 1 (2.6) [1] 0 1 (0.6) [1]
Notes: *Data are presented as number of patients (%) [number of events] and the denominator for % is the number of patients in the column. **Chi-square or Fisher’s 
exact test.
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Ccr, creatinine clearance; FDC, fixed-dose combination; SAEs, serious 
adverse events.
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their use has been extended to preventive treatment for a variety 
of cardiovascular diseases.2 Rosuvastatin is more effective than 
other statins for achieving LDL-C goals and producing favor-
able changes in the atherogenic lipid profile.16,17 Previous studies 
have shown that statins have direct effects on plaque stability, 
nitric oxide metabolism, inflammation, endothelial function, 
and oxidative stress.18,19 Additionally, statins have been shown 
to significantly reduce cardiovascular mortality and morbidity 
in patients at risk for cardiovascular diseases.18,20
The interplay between hypertension and dyslipidemia 
acts through the renin–angiotensin system to increase 
cardiovascular risk. Hypertension and dyslipidemia result 
in the release of angiotensin II, which acts on angiotensin 1 
receptors. Activation of angiotensin 1 receptors stimulates 
NADH oxidase production in endothelial cells, resulting in 
the generation of reactive oxygen species in vascular cells and 
eventually endothelial dysfunction and decreased nitric oxide 
production.21,22 Combinations of ARBs and statins could be 
atheroprotective and effective in improving endothelial func-
tion through their synergistic mode of action on angiotensin 1 
receptors, resulting in the reduction of cardiovascular morbidity 
and mortality.2 FDC therapy with olmesartan medoxomil 
(40 mg) and rosuvastatin (20 mg) could be highly effective for 
the prevention of cardiovascular events through cardiovascular 
protective benefits beyond comprehensive control of both BP 
and blood cholesterol and could potentially increase treatment 
adherence in patients prescribed long-term polymedication.
Olmesartan medoxomil is not metabolized by the cyto-
chrome P450 system and has no effect on P450 enzymes. 
Rosuvastatin clearance is not dependent on metabolism by 
cytochrome P450 3A4 to a clinically significant extent. Thus, 
interactions with drugs that inhibit or induce those enzymes, 
or are metabolized by these enzymes are not expected. 
A previous study showed that FDC therapy with olmesartan 
medoxomil (40 mg) and rosuvastatin (20 mg) has a similar 
pharmacokinetic profile to that of coadministration of each 
drug as individual tablets, without serious AEs.10 These 
results suggested that FDC therapy could be used inter-
changeably with the conventional formulation of the coad-
ministration of each drug separately. In the present study, 
we demonstrated that the efficacy and safety of FDC therapy 
with olmesartan medoxomil (40 mg) and rosuvastatin (20 
mg) were similar to those of each drug in the combination 
in patients with both hypertension and dyslipidemia.
The relatively small sample size would be a limitation 
of the present study. Further investigation of a larger patient 
population over a longer period will be needed to confirm 
the clinical benefit.
Conclusion
For patients who have hypertension and dyslipidemia 
concomitantly, FDC therapy with olmesartan medoxomil 
(40 mg) and rosuvastatin (20 mg) is a good therapeutic option 
with appropriate efficacy and safety. Such a combo-pill may 
help enhance the compliance of the patients with large pill 
burden due to comorbidities.
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Number Site location
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2 Busan Paik Hospital, Busan, Korea
3 chonnam national University hospital, gwangju, Korea
4 chungnam national University hospital, Daejeon, Korea
5 asan Medical center, college of Medicine, University of Ulsan, seoul, Korea
6 Dankook University Hospital, Cheonan, Korea
7 Dong-A University Hospital, Busan, Korea
8 gachon University gil hospital, incheon, Korea
9 inha University college of Medicine, incheon, Korea
10 Kangdong sacred heart hospital, seoul, Korea
11 Keimyung University Dongsan Medical center, Daegu, Korea
12 Korea University anam hospital, seoul, Korea
13 Korea University guro hospital, seoul, Korea
14 Pusan National University Hospital, Busan, Korea
15 samsung Medical center, seoul, Korea
16 Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea
17 Seoul National University Bundang Hospital, Seongnam, Korea
18 seoul national University hospital, seoul, Korea
19 seoul st Mary’s hospital, seoul, Korea
20 soonchunhyang University hospital, seoul, Korea
21 Ulsan University hospital, Ulsan, Korea
22 Wonkwang University Hospital, Iksan, Korea
23 Yeungnam University Medical center, Daegu, Korea
24 Yonsei University gangnam severance hospital, seoul, Korea
25 Yonsei University severance hospital, seoul, Korea
